Ariad Ruling Bolsters Written Description Requirement

Law360, New York (March 23, 2010, 7:14 PM EDT) -- While the ruling in Ariad Pharmaceuticals Inc.’s closely watched patent infringement case against Eli Lilly & Co. confirmed existing law, intellectual property attorneys say the court's decision will shine a spotlight on the U.S. Patent Act's written description requirement — both for patent seekers and for defendants facing accusations of infringement.

Monday's opinion, which was affirmed by nine out of 11 judges in the U.S. Court of Appeals for the Federal Circuit, revisited the written description requirement, but ultimately reaffirmed the court's earlier conclusion that Lilly...
To view the full article, register now.